Josephine van Dongen

4 Rotavirus vaccine effectiveness 107 Acknowledgements Members of the RIVAR study team include: L.M. Zwar t, C. Tims-Polderman, G. van Putten, C. Band and, M. van M Beurden, Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht, the Netherlands.We would also like to thank all RIVAR par ticipants and their parents or guardians, all research nurses of the different study sites for their contribution to this project. A special recognition to dr. vanWerkhoven for assisting on the Bayesian analysis.We thank the Dutch Working Group on Clinical Virology from the Dutch Society for Clinical Microbiology (NVMM) and all par ticipating laboratories for providing the virological data from the weekly Sentinel Surveillance system. Funding sources were the Netherlands Organisation for Health Research and Development (grant number : 836021024), Healthcare Insurers Innovation Foundation, GlaxoSmithKline Biologicals SA (Study ID: 203108) and, UMC Utrecht. Role of the funding source : None of the sponsors had a role in study design, data collection, data analysis, writing or submitting of the study. GlaxoSmithKline Biologicals SA was provided the oppor tunity to review a preliminary version of this manuscript for factual accuracy, but the authors are solely responsible for final content and interpretation. Declaration of Interests : The authors have no financial or personal relationships relevant to this study. None of the authors has any affiliation or received salary from any of the third par ty funders. Trial registration : NTR5361 www.trialregister.nl